QIAGEN

New studies support modern TB blood testing: Is your practice up-to-date?

Responsive image

Thank you

Thank you for your interest in QIAGEN microbiome workflow solutions.
A sales representative will contact you soon with your tailored discount offer.

Register here to watch the webinar today!




I hereby give QIAGEN the consent to contact me via email and phone (subject to the contact information provided above) with further special offers, contests and product information.
For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
For SP creation / could be hidden field
If Opp Type is INSTRUMENT // For SP creation / could be hidden field
If Opp Type is INSTRUMENT // For SP creation / could be hidden field

New studies support modern TB blood testing: Is your practice up-to-date?

Over the past two decades, there has been a growing shift away from using the century-old tuberculin skin test to using a modern blood test with interferon gamma release assays (IGRAs). Today, IGRAs are the preferred test in national guidelines for most routine and high-risk TB screening. However, familiarity of these newer assays has lagged behind the rapid policy changes and growing body of scientific evidence. Since the launch of QuantiFERON-TB Gold Plus (QFT-Plus), there have been new scientific advancements demonstrating the value of CD8 T cell response that provides health care providers with a more comprehensive picture of a patient’s immune response to TB.

Join Dr. Masae Kawamura, Senior Director of Scientific and Medical Affairs for TB diagnostics, QIAGEN, who will provide an overview of testing for TB infection and the scientific evidence behind the growing domestic and global use of IGRAs. Dr. Kawamura will discuss new literature on QFT-Plus and how it performs in high-risk populations. She will also provide the latest case study scenarios for practical application with QFT-Plus, QIAGEN’s fourth-generation IGRA.

QuantiFERON-TB Gold Plus (QFT-Plus) is an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection. QFT-Plus is an indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. QFT-Plus Package Inserts as well as up-to- date licensing information and product-specific disclaimers can be found at www.QuantiFERON.com.

+ Subject to your consent given above, QIAGEN may use your personal information for internal business and marketing purposes. The information will not be sold to any third party. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) solely for the purposes of data hosting and QIAGEN email distribution. You may unsubscribe at any time. Your data will be processed in compliance with applicable privacy laws, including the EU General Data Protection Regulation. For further details, please refer to our Privacy Policy.